SCHEMBL17148796

SCHEMBL17148796

CC1CCCC(O)C1OC1OC(C)C(OCc2ccccc2)C(OCc2ccccc2)C1OCc1ccccc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC6A2 P23975 1/20 0.37
SSTR1 P30872 1/20 0.37
SSTR2 P30874 1/20 0.37
SSTR4 P31391 1/20 0.37
SSTR3 P32745 1/20 0.37
SSTR5 P35346 1/20 0.37
PTPN1 P18031 2/20 0.36
PDPK1 O15530 1/20 0.36
MTOR P42345 1/20 0.36
GJB2 P29033 2/20 0.35
FGF1 P05230 2/20 0.34
FGF2 P09038 2/20 0.34
VEGFA P15692 2/20 0.34
HPSE Q9Y251 2/20 0.34
PTPN2 P17706 1/20 0.34
PTPN11 Q06124 1/20 0.34
BCHE P06276 2/20 0.34
PDE4D Q08499 1/20 0.33
TSHR P16473 1/20 0.33
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2008169 0.88 SSTR1 (0.37) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2014900 0.88 SLC6A2 (0.35) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2008170 0.88 SSTR1 (0.37) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2014901 0.88 SLC6A2 (0.35) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2012812 0.86 BCHE (0.40) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2012813 0.86 BCHE (0.40) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL8779233 0.85 SLC6A2 (0.42) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2013391 0.84 SSTR1 (0.35) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2013392 0.84 SSTR1 (0.35) SLC6A2SSTR1SSTR2SSTR4SSTR3
SCHEMBL2006606 0.84 SLC6A2 (0.37) SLC6A2SSTR1SSTR2SSTR4SSTR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150284420-A1 E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE GLYCOMIMETICS, INC. (US) 2015-10-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150284420-A1 E-SELECTIN ANTAGONIST COMPOUNDS AND METHODS OF USE SELE, SELPLG, SELP SLC6A2 1161/4885SSTR1 3254/4885SSTR2 3523/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.